The Longevity Fund

The Longevity Fund is a U.S. sector-specialist venture capital firm headquartered in San Francisco, California, focused exclusively on investments in life sciences, digital health, oncology / ageing / longevity biology, and impact-oriented health-investing themes aimed at extending human healthspan and lifespan. The firm was founded in 2015 by Founder and General Partner Laura Deming (Thiel Fellow; one of the youngest-ever VCs globally at her 2015 launch; prominent longevity-science-focused investor with prior research experience at MIT's Barbacid Lab and the Buck Institute for Research on Aging). The Longevity Fund invests primarily at seed and Series A stages with typical initial check sizes in the USD 500,000 to USD 3 million range, and has raised multiple institutional funds (Fund I at USD 4 million in 2015, Fund II at USD 37 million in 2019) with aggregate AUM in the USD tens to low-hundreds of millions range. The firm is distinctive for being one of the earliest dedicated-longevity VC funds globally, pre-dating the broader ''longevity VC'' wave. Notable portfolio companies include Unity Biotechnology, Loyal, Precision BioSciences, Metacrine, Navitor Pharmaceuticals, Gordian Biotechnology, and several other age-biology and longevity-adjacent therapeutics companies.